Do not forget Mansanguan et al.'s study on the Cardiovascular Manifestations of Pfizer mRNA COVID-19 Vaccine in Adolescents; Cardiovascular manifestations found in 29% of Thai students aged 13-18 yrs

by Paul Alexander

Cardiovascular manifestations ranged from tachycardia or palpitation to myopericarditis; tachycardia (7.6%), shortness of breath (6.6%), palpitation (4.3%), chest pain (4.3%), hypertension (3.9%)

‘Prospective cohort study enrolled students aged 13-18 years from two schools, who received the second dose of the Pfizer mRNA COVID-19 vaccine.

enrolled 314 participants; of these, 13 participants were lost to follow-up, leaving 301 participants for analysis.

The most common cardiovascular signs and symptoms were tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%), and hypertension (3.99%). One participant could have more than one sign and/or symptom.

Seven participants (2.33%) exhibited at least one elevated cardiac biomarker or positive lab assessments.

Cardiovascular manifestations were found in 29.24% of patients, ranging from tachycardia or palpitation to myopericarditis. Myopericarditis was confirmed in one patient after vaccination. Two patients had suspected pericarditis and four patients had suspected subclinical myocarditis.’